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Objective. To determine whether the Stratum Corneum Chymotryptic Enzyme (SCCE), a novel serine protease known to contribute to the
cell shedding process by catalyzing the degradation of intercellular cohesive structures at the skin surface, is overexpressed in human cervical
tumors.
Methods. SCCE expression was evaluated in 18 cervical cancer cell lines (i.e., 10 primary and 8 established cell lines) as well as in
8 normal cervical keratinocyte cultures by RT-PCR. In addition, SCCE expression was evaluated by immunohistochemistry on paraffin-
embedded tumor tissue.
Results. Normal cervical keratinocytes did not express SCCE. In contrast, 50% of the primary and 50% of the established cervical cancer
cell lines expressed SCCE by RT-PCR. Eighty percent (i.e., four of five) of primary squamous cervical tumors and 20% (i.e., one of five) of
primary adenocarcinomas expressed SCCE. Five out of five (100%) of the patients harboring SCCE-positive tumors were found to have
metastatic involvement of the pelvic tumor draining lymph nodes. Immunohistochemistry staining of paraffin-embedded cervical cancer
specimens confirmed SCCE expression in tumor cells and its absence on normal cervical epithelial cells.
Conclusion. Squamous cervical cancer expressed high levels of SCCE, suggesting that this protease may play an important role in
invasion and metastasis. Because SCCE appears only in abundance in tumor tissue and contains a secretion signal sequence, suggesting that
SCCE is secreted, it may prove to be a useful diagnostic/prognostic tool for the detection of metastatic or recurrent disease or as a novel
molecular target for cervical cancer therapy.
D 2004 Elsevier Inc. All rights reserved.Keywords: Cervical cancer; SCCE; Serine protease
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E-mail address: santinalessandrod@uams.edu (A.D. Santin).blood vessels, and seeding at distant organs, resulting in
tumor-associated metastasis [1–3]. Serine proteases are a
family of protein-degrading enzymes that play crucial roles
in numerous biological processes including activation of
complement, blood coagulation, degradation of extracellular
matrix component, and activation of growth and angiogenic
factors [4,5]. To assess the value of secreted proteases as
markers for tumor detection and targets for therapeutic
intervention, our group has recently developed a screening
strategy using redundant primers to the conserved catalytic
triad domain of the serine protease family. Using this
approach to display serine protease transcripts found in
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expression in normal tissues, we recently reported the
identification and cloning of several transmembrane serine
proteases, including Stratum Corneum Chymotryptic En-
zyme (SCCE/kallikrein 7), in ovarian cancer [6–10]. Orig-
inally characterized by Hansson et al. [11] and Brattsand
and Egelrud [12], SCCE represents a serine protease
expressed in the upper spinous and granular layers of the
epidermis playing a crucial role during keratinocyte cell
shedding (i.e., desquamation). Because of our previously
reported association between SCCE expression and tumor
growth and metastasis in ovarian cancer [7] and the fact that
SCCE appears to catalyze the degradation of intercellular
cohesive structures in the outermost cornified layer of the
skin, in this study, we have evaluated the extent and
frequency of expression of the SCCE gene in several
primary and established cervical cancer cell lines. We report,
to our knowledge for the first time, expression of SCCE on
the majority of squamous cervical tumors evaluated and a
possible association between SCCE expression and meta-
static involvement of tumor draining lymph nodes. These
findings may have important implications for the use of
SCCE protease as a diagnostic/prognostic tool or as a
molecular target for cervical cancer therapy.Materials and methods
Primary and established cervical cancer cell lines
Eighteen cervical cancer cell lines (i.e., 10 primary and
8 established) were evaluated for SCCE expression by RT-
PCR. Commercially available established cervical cancer
cell lines (i.e., CaSki, SiHa, MS-751, HT-3, C33a, Me180,
HeLa, and C4-I) were purchased from the American Type
Culture Collection. Tumors derived from primary speci-
mens were staged according to the FIGO operative staging
system. Fresh tumor biopsies from patients diagnosed with
frankly invasive stage IB– IIA cervical cancer were
obtained at the time of surgery through the Gynecologic
Oncology Division and the Pathology Department, UAMS,
under approval of the Institutional Review Board. Patient
characteristics are described in Table 1. Radical abdominalTable 1
Characteristics of the patients
Patient Age Race Stage Treatment Lymph nodes status
CVX 1 40 White I B surgery 
CVX 2 26 White I B surgery +
CVX 3 38 Afro-American I B surgery +
CVX 4 40 White IIA surgery +
CVX 5 42 White I B surgery +
ADX 1 33 White I B surgery +
ADX 2 33 Afro-American I B surgery 
ADX 3 27 White I B surgery 
ADX 4 50 Afro-American I B surgery 
ADX 5 46 White I B surgery hysterectomy and lymph node dissection for invasive
cervical cancer were performed in all patients. Eight
normal keratinocyte (KRT) control samples (i.e., four
primary keratinocyte cultures and four flash-frozen biop-
sies) were obtained from cervical biopsies of hysterectomy
specimens from women diagnosed with benign disease and
with a previous report of a normal cytological evaluation.
Cervical cancer and normal keratinocyte cell lines were
established following previously reported standard tissue
culture techniques [13]. We studied 10 primary cervical
cancer and 4 primary keratinocyte cell lines, some of
which had been cultured for 3–4 weeks and others over
a much longer period of time. Purity of fresh tumor
cultures was tested by morphology, immunohistochemistry
staining, and/or flow cytometry with antibodies against
cytokeratins. Only cell lines containing more than 99%
tumor cells were evaluated. Because tissue digestion and
prolonged in vitro cell culture may potentially alter antigen
expression, four adjunctive normal cervical keratinocyte
biopsies were also evaluated for SCCE expression before
enzymatic digestion and/or in vitro culture (i.e., snap
frozen in liquid nitrogen immediately after collection).
RNA isolation and cDNA synthesis
RNA isolation from different cell lines was performed
using TRIzol Reagent (Invitrogen) according to the manu-
facturer’s instructions. To verify integrity, 4 Ag of RNA
from each sample was run in 1% agarose gel using 18S +
28S Ribosomal RNA (Sigma) as positive control. First-
strand cDNAwas synthesized using 5 Ag of total RNA, 1 
RT-PCR buffer, 5 mM MgCl2, 1 mM dNTPs, 2.5 AM
random hexamers, 1 U/Al Rnase Inhibitor, and 2.5 U/Al of
MuLV Reverse transcriptase (Gene Amp RNA PCR kit;
Applied Biosystems) in a total volume of 20 Al. RNA
extracted from CaOV3 serous papillary ovarian cancer cell
line, previously reported to express SCCE [7], was used as a
positive control.
PCRs
The PCR reaction mixture consisted of cDNA, 0.4 AM
of sense and antisense primers, 2.5 mM MgCl2, 0.2 mM
dNTPs, 0.025 U/Al Taq polymerase (Gene Amp RNA
PCR kit; Applied Biosystems) with reaction buffer in a
total volume of 50 Al. The target sequences were ampli-
fied in parallel with h-tubulin gene. Thirty-five cycles of
PCR were performed in a Gene Amp PCR System 2700
(Applied Biosystems). Each PCR cycle included 30 s of
denaturation at 95jC, 30 s of annealing at 58jC, and 30
s of extension at 72jC. The sequences of the SCCE
specific primers that produce the 339-bp product were as
follows: 5V-AGATGAATGAGTACACCGTG-3V forward
and 5V-CCAGTAAGTCCTTGTAAACC-3V reverse. The
sequences of h-tubulin primers that produce the 454-bp
product were as follows: 5V-CGCATCAACGTGTACTA-
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GAGA-3V reverse. These primers span an intron such
that the PCR products generated from pure cDNA can be
distinguished from cDNA contaminated with genomic
DNA.
Antibody production and immunohistochemistry
Polyclonal antibodies were generated by immuniza-
tion of white New Zealand rabbits with one of two
poly-lysine-linked multiple antigen peptides derived from
the amino acid sequence of SCCE as previously repor-
ted [7]. These sequences are PLQILLLSLALE and
SFRHPGYSTQTH. Formalin-fixed, paraffin-embedded
tissue blocks from 8 normal uterine cervix (i.e., con-
trols) and 10 invasive cervical carcinomas of the uterus
(5 squamous carcinomas and 5 adenocarcinomas) from
which primary cell lines were established were retrieved
from the surgical pathology files of the University of
Arkansas for Medical Sciences (UAMS) and evaluated
for SCCE expression. Study blocks were selected after
histopathologic review. The most representative hema-
toxylin and eosin-stained block sections were used for
each specimen. Immunohistochemical staining was per-
formed using a Vectastain Elite ABC Kit (Vector
Laboratories, Burlingame, CA). Briefly, formalin-fixed
and paraffin-embedded specimens were routinely depar-
affinized and processed using microwave heat treatment
in 0.01 M sodium citrate buffer (pH 6.0). The speci-
mens were incubated in methanol with 0.3% H2O2 for
30 min at room temperature and then incubated with
normal goat serum for 30 min. The samples were
incubated with anti-SCCE peptide-derived polyclonal
antibody for 1 h at room temperature in a moisture
chamber, followed by incubation with biotinylated anti-
rabbit IgG for 30 min, and then incubated with ABC
reagent (Vector Laboratories) for 30 min. The final
products were visualized using the AEC substrate sys-
tem (DAKO, Carpenteria, CA), and sections were
counterstained with hematoxylin before mounting. Neg-
ative controls were performed by using normal serum
instead of the primary antibody.Fig. 1. SCCE expression by RT-PCR on primary squamous cell carcinoma (CVX-
primary cell lines. The reaction products were electrophoresed through a 2% agaros
tubulin product, and the 339-bp band represents the SCCE product. SCCE mRNA
cell lines tested. In contrast, 80% (i.e., four out of five) of the squamous cell and 2Statistical analysis
Data were analyzed using the two-tailed t test, and
Student’s t test for paired data. In all tests, the difference
was considered significant when P values were less than
0.05.
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SCCE expression in primary and established cervical
cancer cell lines
To characterize the frequency of expression of the SCCE
gene in cervical tumors, we used RT-PCR with cDNA
derived from primary and established squamous and ade-
nocarcinoma cervical cancer cell lines as a template. Cul-
tures of normal cervical keratinocytes were used as controls.
PCR primers that amplify a SCCE-specific 339-bp product
were synthesized and used in reactions. Primers that pro-
duce a specific 454-bp PCR product for h-tubulin were also
used as internal controls. Of the 18 cervical carcinomas
studied, 9 (50%) were found to express SCCE by RT-PCR.
Fig. 1 shows an ethidium bromide-stained agarose gel with
the separated RT-PCR products for normal cervical kerati-
nocytes and primary cervical cancer cell lines, while Fig. 2
shows the RT-PCR results for the established cervical cancer
cell lines. Both are representative of the typical results
observed. Flash-frozen samples or cultures of normal cer-
vical keratinocytes did not express SCCE (Figs. 1 and 2). In
contrast, SCCE was found to be expressed in 50% (i.e., 5 of
10) of primary cervical cancer cell lines (P < 0.01) and in
50% (i.e., 4 of 8) of established cervical cancer cell lines
(P < 0.01). Importantly, when individual histological sub-
types of primary tumors were evaluated, SCCE expression
was found in four out of five (80%) of the primary
squamous cervical tumors and one out of five (20%) of
the adenocarcinomas.
Five out of ten of the early-stage cervical cancer patients
from which primary cell lines were successfully established
in vitro presented with metastatic involvement of the pelvic
lymph nodes (Table 1). Strikingly, all patients for whom the1-5), primary adenocarcinoma (ADX1-5), and normal cervical keratinocyte
e gel and stained with ethidium bromide. The 454-bp band represents the h-
expression was not detected in any of the four normal cervical keratinocyte
0% (i.e., one out of five) of the cervical adenocarcinomas expressed SCCE.
Fig. 2. SCCE expression by RT-PCR on established cervical cancer cell lines and normal keratinocyte flash-frozen biopsies. The reaction products were
electrophoresed through a 2% agarose gel and stained with ethidium bromide. The 454-bp band represents the h-tubulin product, and the 339-bp band
represents the SCCE product. SCCE mRNA expression was not detected in any of the four normal cervical keratinocyte samples tested. In contrast, 50% (i.e.,
four out of eight) of the established cell lines expressed SCCE.
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CVX-4, CVX-5, and ADX-1 = 100%) were found to harbor
metastatic disease in the tumor draining lymph nodes.
Immunohistochemistry staining
To determine whether SCCE expression detected by RT-
PCR in primary cervical cancer cell lines is the result of a
selection of a subpopulation of cancer cells present in the
original tumor, or whether in vitro expansion conditions
may have modified gene expression, we performed immu-
nohistochemical analysis of SCCE protein expression on
formalin-fixed paraffin-embedded tumor tissue from all
primary tumors from which primary cell lines were derived.
As shown in Table 2, immunohistochemical staining sup-
ported the data obtained by RT-PCR. Using a SCCE
peptide-directed antibody, we observed no significant stain-
ing with normal cervical keratinocytes samples (Fig. 3A). In
contrast, intense staining was associated with cervical tumor
cells of both adenocarcinoma and squamous histological
subtypes (Figs. 3C and D). Both adenocarcinoma andTable 2
SCCE expression in squamous and adenocarcinoma cervical cancers and
normal keratinocytes by immunohistochemistry


















KRT 8 squamous cell carcinoma specimens (Figs. 3C and D,
respectively), similarly to ovarian cancer cells (i.e., positive
control, Fig. 3B), showed diffuse cytoplasmic and cell
membrane staining for SCCE.Discussion
In the process of studying proteolytic enzymes playing a
key role in tumor metastatic processes, we have recently
identified overexpression of SCCE as well as other serine
proteases in a high percentage of ovarian cancers [6–10].
Because SCCE is known to catalyze the degradation of
intercellular cohesive structures at the skin surface and thus
may play a role during the metastatic process of cervical
cancer, in this work we have analyzed the expression of the
novel serine protease SCCE in several primary cultures as
well as established cervical cancer cell lines. We chose this
approach to evaluate differential SCCE gene expression in
highly enriched populations of cervical tumor-derived epi-
thelial cells. We report that SCCE is highly expressed in
80% of the primary squamous cervical cancer cell lines
studied whereas it is undetectable in normal cervical kera-
tinocytes. These data therefore support the view of SCCE as
a highly differentially expressed serine protease in squa-
mous cervical tumors when compared to normal control
cells (i.e., cervical keratinocytes). In contrast, only 20% of
the cervical adenocarcinoma were found to express SCCE.
To validate gene expression data at protein level, SCCE
expression was evaluated by immunohistochemistry on
paraffin-embedded tissue from which all primary tumor cell
lines were established. All primary uncultured tumor speci-
mens from which SCCE expression was detected by RT-
PCR expressed SCCE by immunohistochemistry. These
included four out of five (80%) primary squamous carcino-
ma and one out of five (20%) primary adenocarcinoma,
confirming that SCCE protein expression is detectable on
SCCE RNA-positive cervical cancer cells. Because the
biological aggressiveness of neoplastic cells lies in their
ability to proliferate abnormally, invade normal host tissues
and metastasize to distant sites, and proteases may provide a
variety of services that assist in the process of tumor
Fig. 3. Immunohistochemical analysis of SCCE expression in cervical tumors. Representative immunoreactivity of SCCE in normal epithelial cells (A) (200),
ovarian serous papillary carcinomas (positive control) (B) (400), adenocarcinoma ADX-1 (C) (400), and cervical squamous cell carcinoma CVX-3 (D)
(400). While no staining is observed in normal cervical keratinocytes, in both squamous cell carcinoma and adenocarcinomas, SCCE shows diffuse staining
throughout all tumor cells.
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SCCE on cervical tumor cell surfaces may play an important
role during cervical cancer metastatic spread. Consistent
with this view, we found that all cervical cancer patients
overexpressing SCCE on their tumors (i.e., four out of four
of the squamous cell carcinoma, and one out one of the
adenocarcinoma, respectively) were harboring metastatic
disease in their pelvic lymph nodes. Thus, although our
study population of 10 early-stage cervical cancer patients is
small and further studies will be necessary to validate our
findings, nevertheless, these data seem to suggest that SCCE
overexpression in cervical cancer may identify a group of
aggressive tumors characterized by the ability to metastasize
early to the regional lymph nodes. Taken together, these data
suggest that future research assessing the clinical usefulness
of SCCE as a marker for early identification of cervical
cancer patients with high risk of lymphatic involvement
might be worthwhile.
Because SCCE appears in abundance in a significant
percentage of squamous cell carcinoma and SCCE can be
released, as suggested by immunohistochemical data
[7,11,12], this protease may prove to be a useful tool for
monitoring response to primary treatment and/or the early
detection of recurrent/persistent cervical cancer after stan-
dard therapy. Indeed, a serum tumor marker that accurately
reflects the active tumor status of the majority of patients
with cervical cancer would be particularly useful in the latter
setting where the distinction between radiation fibrosis and
disease recurrence may be extremely difficult. Consistent
with this view, PSA and kallikrein 2 have already been
validated as potential tumor markers for the early diagnosis
or recurrence of prostate cancer due to their abnormalprevalence in the peripheral blood of patients [14]. Further-
more, other secreted members of the serine proteases family
including kallikrein 5, 10, 11, and 14 are in the process of
being validated as novel cancer biomarkers in other human
solid tumors [15–20]. To validate this hypothesis, an
ELISA detection kit for quantification of SCCE in the
circulation of ovarian and cervical cancer patients is under
development in our laboratory.
The recognition of tumor antigen loaded dendritic cells
(DC) as one of the most promising approaches to induce a
tumor specific immune response in vivo has recently gen-
erated widespread interest in the use of these ‘‘natural
adjuvants’’ for the therapy of several human malignancies
refractory to standard treatment modalities [21]. The iden-
tification and cloning of a group of preferentially expressed
serine proteases including SCCE as novel tumor-associated
antigens may therefore offer the opportunity to use these
targets to assess the potential for therapeutic DC vaccination
for the treatment of human cancer patients refractory to
standard treatment modalities [22]. Indeed, the lack of
SCCE transcript presence in all normal adult and fetal
tissues examined so far, with the exception of the desqua-
mating stratum corneum of the skin [7], support the poten-
tial of this secreted extracellular enzyme as a useful
therapeutic marker for ovarian and cervical carcinoma.
Supporting this view, our laboratory has recently identified
cytotoxic T lymphocyte (CTL) epitopes within SCCE [22].
These data, combined with the recently reported immuno-
dominant role played by other serine proteases (i.e., PSA) in
the prostate cancer-specific immune response induced by
DC transfected with amplified tumor RNA [23] or loaded
with killed prostate cancer cells [24], further suggest that
A.D. Santin et al. / Gynecologic Oncology 94 (2004) 283–288288peptide epitopes derived from SCCE may become selective
targets for DC-driven CD8+ CTL against cervical cancer.
In conclusion, we have shown that squamous cervical
cancer cell lines, but not normal cervical epithelial cells,
frequently overexpress the SCCE gene, and we have further
demonstrated that cervical tumors expressed this secreted/
membrane-associated serine protease. In addition, we have
reported evidence that SCCE expression may identify a
group of cervical tumors endowed with the ability to
metastasize early during disease progression to tumor drain-
ing lymph nodes. On the basis of these findings, we suggest
that SCCE has the potential to become a useful diagnostic/
prognostic tool for identifying biologically aggressive cer-
vical tumors, monitoring response to therapy as well as
serve as a novel target antigen for the treatment of cervical
tumors refractory to standard treatment modalities. The
future design and implementation of clinical trials will
ultimately determine the validity of this approach.Acknowledgments
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